Friday, 16 October 2026European Markets

SAS AB Stock Is 17% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of SAS AB (Oslo Børs Benchmark Index_GI: SASNO.OL) jumped by a staggering 17.4% in 5 sessions from kr0.28 to kr0.33 at 14:38 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 1.22% to kr1,198.22, after two consecutive sessions in a row of gains.

SAS AB's last close was kr0.33, 66.66% under its 52-week high of kr0.98.

About SAS AB

SAS AB (publ), together with its subsidiaries, provides passenger flight transportation services in the Nordic and international route network. The company also offers air cargo services, in-flight sales, ground handling, and technical maintenance services, as well as travel-related loyalty programs. It operates a fleet of 135 aircraft, including 12 long-haul aircraft, 95 short-haul aircraft, and 28 aircraft flown by regional production partners. The company was founded in 1946 and is headquartered in Stockholm, Sweden. On July 5, 2022, SAS AB (publ), along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Earnings Per Share

As for profitability, SAS AB has a trailing twelve months EPS of kr-1.24.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1151.97%.

Volume

Today's last reported volume for SAS AB is 1674758 which is 82.49% below its average volume of 4172810.

More news about SAS AB (SASNO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com